| EMA number | EMEA/H/C/003691 |
| ATC code | B06A |
| Authorisation | 29 May 2019 |
| Withdrawn | 24 March 2022 |
| Revision | 5 |
Zynteglo is indicated for the treatment of patients 12 years and older with transfusion-dependent β thalassaemia (TDT) who do not have a β0/β0 genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.